EUVIMEDEUVIMED entdecken
Crossref

Farrerol alleviates obesity and hepatic steatosis by targeting translational regulation to coordinate cellular stress and lipid metabolism

Shuting Huang, Jingyi Wang, Shouxiu Ma, Liangze Li, Shulin Sun, Ying Zhou, Cheng Qian, Mu Zhang, Yu Liu

Phytomedicine · 2026

DOI: 10.1016/j.phymed.2026.158355 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2026. Verfasst von Shuting Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Sir Runrun Hospital, Nanjing Medical University, 211100, China. Hauptthemen laut MEDLINE: Lipid Metabolism, Obesity, Fatty Liver. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Jiangsu Commission of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Dysregulation of lipid metabolism is a primary driver of obesity and related metabolic disease. Farrerol is a dihydroflavonoid derived from Rhododendron dauricum L., has known anti-inflammatory and antioxidant properties, but its potential role in regulating lipid metabolism and the underlying mechanisms remains unclear. PURPOSE: This study aimed to investigate the effect of farrerol on lipid metabolism and explore its potential molecular mechanisms using multi-model systems. METHODS: The lipid-lowering efficacy of farrerol was initially evaluated in Caenorhabditis elegans (C. elegans) under physiological and citrate-induced high-fat conditions. RNA-seq and RNA interference (RNAi) screening were utilized to identify genes involved in the lipid-regulating effect of farrerol. The lipid-lowering effects and mechanisms were further validated in vitro and in vivo using biochemical assays, untargeted lipidomics, and target-identification approaches including DARTS and CETSA. RESULTS: In C. elegans, farrerol treatment reduces lipid accumulation induced by citric acid and promoted DAF-16 nucelar translocation. RNA-seq and RNAi screening identified F44E5.4/F44E5.5 and uev-2 as essential upstream regulators for lipid lower effect and DAF-16 activation. In vitro and in vivo, farrerol effectively suppressed hepatic steatosis, modulated hepatic lipid profiles by reducing highly lipotoxic triglycerides, and ameliorated hyperinsulinemia in DIO mice. Mechanistically, target screening revealed that farrerol directly binds to eukaryotic translation initiation factor 4 gamma 1 (eIF4G1). This interaction rescues the expression of the chaperone HSP72, the mammalian ortholog of F44E5.4/5.5, which in turn stabilizes AMPK, thereby inhibiting SREBP1-mediated de novo lipogenesis. CONCLUSION: Farrerol alleviates lipid accumulation through a conserved eIF4G1/HSP72/AMPK signaling across species. These findings highlight the direct molecular target of farrerol and support its potential as a promising natural therapeutic agent for obesity and hepatic steatosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lipid MetabolismObesityFatty LiverAnimalsCaenorhabditis elegansRNA InterferenceMiceStress, PhysiologicalMaleCaenorhabditis elegans Proteins

Stichwörter der Autor:innen

AMPKC. elegansFarrerolLipid metabolismeIF4G1

Substanzen

Caenorhabditis elegans Proteins

Autor:innen und Institutionen

  • Department of Endocrinology, Sir Runrun Hospital, Nanjing Medical University, 211100, China.
  • Department of Pathology, School of Basic Medical Sciences, Nanjing Medical University, 211166, China; NHC Key Laboratory of Antibody Technique, Nanjing Medical University, 211166, China.
  • Department of Pathology, School of Basic Medical Sciences, Nanjing Medical University, 211166, China; NHC Key Laboratory of Antibody Technique, Nanjing Medical University, 211166, China. Electronic address: ctsien@163.c…
  • Department of Endocrinology, Sir Runrun Hospital, Nanjing Medical University, 211100, China. Electronic address: amu1989@126.com.
  • Department of Endocrinology, Sir Runrun Hospital, Nanjing Medical University, 211100, China. Electronic address: drliuyu@njmu.edu.cn.

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Jiangsu Commission of Health

Zitieren

APA

Huang, S., Wang, J., Ma, S., Li, L., Sun, S., Zhou, Y., Qian, C., Zhang, M., & Liu, Y. (2026). Farrerol alleviates obesity and hepatic steatosis by targeting translational regulation to coordinate cellular stress and lipid metabolism. Phytomedicine. https://doi.org/10.1016/j.phymed.2026.158355

Vancouver

Huang S, Wang J, Ma S, Li L, Sun S, Zhou Y, et al. Farrerol alleviates obesity and hepatic steatosis by targeting translational regulation to coordinate cellular stress and lipid metabolism. Phytomedicine. 2026. doi:10.1016/j.phymed.2026.158355

BibTeX
@article{Huang2026,
  author = {Huang, Shuting and Wang, Jingyi and Ma, Shouxiu and Li, Liangze and Sun, Shulin and Zhou, Ying and Qian, Cheng and Zhang, Mu and Liu, Yu},
  title = {Farrerol alleviates obesity and hepatic steatosis by targeting translational regulation to coordinate cellular stress and lipid metabolism},
  journal = {Phytomedicine},
  year = {2026},
  doi = {10.1016/j.phymed.2026.158355}
}
Kostenlos starten →